HGH Fragment 176-191: The Unmodified Fragment vs AOD-9604

At a Glance

Of all the fat-loss peptides sold online, HGH Fragment 176-191 has one of the better scientific origin stories and one of the weaker evidence bases. The gap between those two facts is the point of this page.

The origin story is genuine. From the late 1970s through the 1990s, a group at Monash University worked out which part of the growth hormone molecule carries its effects on fat metabolism. They located it in the C-terminal region, synthesised that fragment, and showed in rats and mice that it reduced lipogenesis and body-weight gain. That is real, citable science [1, 2, 3, 4].

What happened next is the part vendors leave out. Pharmaceutical development went to a modified version of the fragment — AOD-9604, with a tyrosine added at the N-terminus — because that was the patentable, stabilised molecule. AOD-9604 went through six developer-run human trials. Tolerability was good. The weight loss was not clinically meaningful, and development as an obesity drug stopped. The site’s AOD-9604 article covers that programme in detail.

So the honest verdict on HGH Fragment 176-191: the mechanism is plausible and the rodent data are real, the human data for the nearest tested relative are negative on efficacy, and the molecule actually being sold has never been in a human trial of any kind. One sentence to hold onto: the version with human trials failed on efficacy, and the version without human trials is the one on sale.

Fragment 176-191 vs AOD-9604: what is actually different

The confusion is not the reader’s fault. Vendors use the names interchangeably, and a 2026 peer-reviewed review of self-administered GH-axis peptides refers to “the GH fragment — AOD9604 (hGH 176-191)” as a single entity [7]. Here is the distinction that matters:

The practical consequence: when someone cites “the clinical trials” for HGH Fragment 176-191, they are almost always citing AOD-9604’s trials — and those trials are a reason for scepticism, not for optimism.

How it works

Growth hormone does several unrelated things: it promotes growth through IGF-1, it alters glucose handling, and it mobilises fat. The structural insight behind this family of compounds is that those functions map to different parts of the molecule, so the fat-handling part can in principle be isolated.

Work on the synthetic C-terminal fragment established three things in rodent tissue and whole animals:

• Antilipogenic activity. hGH(177-191) suppressed lipogenesis in adipose tissue with activity described as identical to that of intact hGH. Notably, the same study found no significant lipolytic effect as measured by glycerol release from epididymal fat pads of treated rats [2] — in that model the fragment blocked fat synthesis rather than breaking fat down.
• Reduced fat mass in obese mice. Chronic treatment with hGH(177-191) reduced cumulative body-weight gain and adipose tissue mass, with inhibited adipose lipogenesis [3].
• Effects on adipocyte glucose transport, demonstrated in rat adipocytes [4].

For the modified analogue the mechanistic picture was extended: AOD-9604 does not compete for the hGH receptor and does not induce cell proliferation, and unlike full-length hGH it did not cause hyperglycaemia or reduce insulin secretion in obese mice while still increasing fat oxidation [6]. In obese Zucker rats, oral AOD-9604 at 500 mcg/kg for 19 days cut body-weight gain by more than half versus control, with insulin sensitivity preserved on euglycaemic clamp [5].

One historical detail cuts against the marketing. The earliest paper in this series, from 1978, is titled Hyperglycemic action of synthetic C-terminal fragments of human growth hormone [1]. Different fragment boundaries in that early work produced a hyperglycaemic effect. The exact residues matter — which is precisely the problem with a vial whose contents you cannot verify.

What the evidence shows

Human evidence: none for this molecule

There are no published human trials of unmodified HGH Fragment 176-191. Not a pharmacokinetic study, not a dose-finding study, not a weight-loss study. Any claim of human efficacy for this compound is either borrowed from AOD-9604 or invented.

Human evidence for the nearest tested relative

AOD-9604 was taken through six randomised, double-blind, placebo-controlled trials by its developer, at 0.25, 0.5 and 1 mg daily, with the largest trial running 24 weeks. The pooled safety summary found tolerability indistinguishable from placebo, with unchanged IGF-1 and glucose tolerance. Efficacy was reported mainly by the developer and never published in full in a peer-reviewed journal; the larger, later trial did not show clinically meaningful weight loss against placebo, and obesity development stopped. Those details, with references, are in the AOD-9604 article.

Animal and cell evidence (clearly labelled as such)

That is the entire mechanistic base, and it is roughly 25 years old. There is no modern replication from an independent group, no primate data, and no human pharmacokinetics for the unmodified fragment.

A note on the 2022 cancer-cell paper

A 2022 study used human growth hormone fragment 176-191 to enhance the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells [9]. It is sometimes cited as evidence that the fragment “has anticancer activity”. It is a nanoparticle drug-delivery study in a cell line: it says nothing about fat loss, and nothing about safety or efficacy in people.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Why fasted dosing is the convention. The rationale given in practice protocols is that insulin blunts the fragment’s effect on adipose tissue, so doses are timed away from meals. That is mechanistically reasonable given the antilipogenic mechanism and the adipocyte glucose-transport data [4], and it has never been tested in a human study. Treat it as a plausible convention, not a validated one.

Stacks commonly used.

• With a GH secretagogue (CJC-1295/ipamorelin, tesamorelin, MK-677), the stated logic being a GH pulse plus peripheral fat mobilisation. No such combination has been tested in a controlled human trial. See CJC-1295 / ipamorelin and ibutamoren (MK-677).
• With fasted cardio — the most commonly described protocol element, and the one that most plausibly accounts for reported results.
• With a GLP-1 agonist, increasingly described. The honest framing matters here: tirzepatide produces about 21% weight loss in a 2,539-person randomised trial and the fragment has no human data, so if both are in a protocol, one of them is doing the work.
• Reconstitution, needle choice and injection technique: peptide injection guide.

What people report: what works and what doesn’t

Sources: the published literature above; the 2026 peer-reviewed review of GH-axis peptide self-administration [7] and the 2026 critical review of peptide use in sport [8]; protocol compilations at peptideprotocolwiki.com; and the open community record on r/Peptides. Community material shows patterns, not proof; no individual account is treated as evidence.

Reported to work

• Mild appetite reduction and a subjective sense of easier fat loss during a calorie deficit, usually described over 6–12 weeks.
• Absence of the side effects people fear from growth hormone — no water retention, no carpal tunnel symptoms, no joint pain. This is the most consistent positive report, and it matches both the mechanism and the AOD-9604 safety data.
• Tolerability generally: injection-site reactions are the main complaint.

Mixed or unclear

• Whether anything happens at all beyond the diet. This is the central ambiguity of the anecdotal record: reports of success are nearly always accompanied by an aggressive deficit, fasted training, or a concurrent GLP-1 drug.
• Localised fat loss at injection sites. Reported, not studied, and not predicted by the mechanism.
• Dose-response. People report no clear difference between 250 and 500 mcg/day, which is what you would expect either from a flat dose-response or from no effect at all.

Reported not to work / disappointing

• Visible fat loss without dietary change. The dominant disappointment, and consistent with the trial history of the related molecule.
• Any effect on muscle, strength or recovery. The fragment does not touch the IGF-1 axis, so this is a mechanism-consistent non-effect — people who expect GH-like recomposition are reliably let down.
• Matching GLP-1-class results. Not close, and not a fair comparison: one side has 2,500-person randomised trials and the other has none.
• Product inconsistency. The same protocol producing different results from different vendors is a recurring theme, and that is a sourcing problem — see peptide sourcing.

What a properly designed human trial would need to show: that the unmodified fragment is absorbed and detectable at defined subcutaneous doses, and that over 12–24 weeks against placebo, with diet held constant, it produces fat-mass loss on DXA. The AOD-9604 programme ran approximately that design on the modified molecule without finding a clinically meaningful effect, which is why nobody has funded the equivalent trial for the unmodified one.

Safety and side effects

What the related human data show. In the AOD-9604 trials, using pharmaceutical-grade material under trial conditions, tolerability was indistinguishable from placebo: IGF-1 unchanged, glucose tolerance unchanged, liver enzymes unaffected, no anti-drug antibodies detected in those tested.

What is reported in practice. Injection-site redness and irritation; occasional transient headache or fatigue. The absence of GH-type side effects is the consistent theme.

What is unknown. Everything specific to the unmodified fragment in humans: absorption, half-life, immunogenicity, long-term effects. The 2026 review of GH-axis peptides is blunt that the adverse-effect spectrum across self-administered peptides in this family spans endocrine and metabolic disturbance, with the underlying problem being unregulated products used without monitoring [7].

Grey-market risk, which is the real risk here. Research-use-only material is not manufactured or tested for human administration. For a short peptide with two cysteines, the specific concerns are incorrect sequence or disulfide pairing, peptide-related impurities, bacterial endotoxin, and wrong concentration. None of the reassuring trial safety data transfer to a vial of unverified content.

Contraindications and cautions. Pregnancy and breastfeeding; active malignancy (the mechanism is not GH-like, but the honest position is that nobody has studied it in that setting); diabetes treated with insulin or secretagogues, where any agent altering adipose glucose handling warrants monitoring. Competitive athletes: prohibited, see below.

Legal and regulatory status

United States. Not an approved medicine. AOD-9604 appears on FDA’s list of bulk substances previously nominated for 503A compounding whose nominations were withdrawn, with FDA’s stated concerns including immunogenicity and peptide-related impurities; it is not in category 1, so the interim enforcement policy does not cover it. The unmodified fragment has no separate regulatory footprint, which means no pathway rather than a permissive one. What the categories actually mean is covered in the FDA 2026 compounding update.

European Union and Germany. No EMA or BfArM authorisation. Importing research chemicals for personal injection is legally exposed, and no pharmacy-grade product exists.

Sport. WADA prohibits growth hormone fragments under S2.2.3 at all times, in and out of competition. This is not a grey area — AOD-9604 and hGH fragments are explicitly covered, and the 2026 review literature treats them as established doping agents [8]. See peptides and WADA rules.

How it fits: the fat-loss peptide shelf

Where this leaves the compound: HGH Fragment 176-191 is an interesting piece of 1990s endocrinology being sold as a 2026 fat-loss product. The mechanism is real, the molecule has never been studied in a person, and the one serious attempt to turn this biology into a medicine ended in a failed efficacy trial. In an era where an approved weekly injection produces a fifth of body weight in a randomised trial, the opportunity cost of spending twelve weeks on an untested fragment is the strongest argument against it — stronger than any safety argument.

For anyone who is going to use it regardless, the two things that matter most are sourcing (a certificate of analysis for the actual lot, not a vendor claim) and honesty about confounders: if the protocol includes a steep deficit, fasted cardio and a GLP-1 drug, the fragment is not what is producing the result.

Related Articles

• AOD 9604 Peptide: The hGH Fragment for Fat Loss and Tissue Repair — the modified analogue that actually went through human trials.
• Tirzepatide: The Dual GIP/GLP-1 Agonist in Full — what evidence-based pharmacological fat loss looks like.
• CJC-1295/Ipamorelin: Growth Hormone Secretagogues — the GH-axis peptides this is usually stacked with.
• Ibutamoren (MK-677) — the oral secretagogue, and why raising IGF-1 is a different trade-off.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules — S2.2.3 in context.
• Peptide Sourcing: Pharmaceutical-Grade vs Grey Market — the decisive practical issue for an unapproved fragment.